178 results about "Humanized antibody" patented technology

Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression.

The present invention relates to antibody-drug conjugates (ADCs) that target the receptor uPARAP, and in particular to antibody-drug conjugates (ADCs) comprising humanized antibodies directed against uPARAP, and their use in delivering active agents to cells and tissues expressing exatecan derivatives and uPARAP. The present invention further relates to the use of the ADCs in the treatment of diseases involving uPARAP-expressing cells, such as certain cancers.

The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 4 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity with secretion of cytokine IFN-gamma in CAR-T cells in vitro and in vivo.

Disclosed are a CD24 antibody or an antigen-binding fragment thereof and the medical use thereof. Further, disclosed are a chimeric antibody comprising CDRs of the CD24 antibody, a humanized antibody, a pharmaceutical composition comprising the CD24 antibody or the antigen-binding fragment thereof, and the use thereof as an anticancer drug.

The present invention provides humanized antibodies targeting CD7, as well as multispecific antibodies, chimeric antigen receptors, antibody conjugates, pharmaceutical compositions and kits comprising the same, and their use in the diagnosis / treatment / prevention of diseases associated with CD7 expression.

The invention discloses an anti-human OX40 inhibitory antibody or an antigen binding fragment thereof, a preparation method and application, and belongs to the technical field of biological immunity. The EC50 of the human-mouse chimeric antibody Y07-L2 and the EC50 of the combination of the humanized antibody Y07-C2 and the human OX40, which are prepared by the invention, are close to those of a targeted antibody drug KHK-4083 for inhibiting the OX40. A heavy chain variable region of the human-mouse chimeric antibody Y07-L2 is as shown in SEQ ID NO.14, and a light chain variable region of the human-mouse chimeric antibody Y07-L2 is as shown in SEQ ID NO.15; the heavy chain variable region of the humanized antibody Y07-C2 is as shown in SEQ ID NO.20, and the light chain variable region of the humanized antibody Y07-C2 is as shown in SEQ ID NO.21; the CDR region of the humanized antibody Y07-C2 is mutated, and the mutant antibodies Y07-C2MH4 and Y07-C2MH4L3 are obviously superior to other antibodies.

Anti-4-1BB single domain antibodies and polypeptides, e.g., bispecific antibodies and chimeric antigen receptors comprising these single domain antibodies, are provided. These antibodies, including humanized antibodies, exhibit superior activity and are suitable for use in various bispecific antibody formats. Methods of using the antibodies or polypeptides to treat and diagnose diseases, e.g., cancer, are also provided.

The present invention provides anti-CD155 antibodies and their applications, and provides anti-CD155 chimeric antibodies, humanized antibodies, and affinity-matured humanized antibodies, which specifically target and bind to the CD155 receptor, inhibit the binding of CD155 to its receptors TIGIT, CD96, and CD226, and have the characteristic of not inducing apoptosis of CD155 cells.

The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 4 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. A preferred co-stimulatory domain is CD28 or 41-BB. The humanized BCMA-CAR-T cells have specific killing activity with secretion of cytokine IFN-gamma in CAR-T cells in vitro and in vivo.

Provided herein are a humanized anti-alpha-2-delta-1 monoclonal antibody and an application thereof. Specifically provided is a humanized antibody, or a biologically active fragment derived from the antibody, that binds to a voltage-gated calcium channel alpha-2-delta-1 subunit (subtype 5). The antibody or the biologically active fragment derived from the antibody, either alone or in combination with lenvatinib, is capable of significantly inhibiting the self-renewal capacity of liver cancer cells and the growth of transplanted tumors in animals. The antibody, either alone or in combination with lenvatinib, can be used for a combination of liver cancer drugs targeting liver cancer stem cells, and can also be used for the in vivo diagnosis of alpha-2-delta-1+ tumors.

The present invention relates to humanized MUC1 antibodies, antibody drug conjugates (ADCs) comprising such antibodies, and their use for the treatment of disorders such as cancer, in particular in the case of MUC1 overexpression.

Provided are a CD19-targeting humanized antibody and chimeric antigen receptor, and the use thereof. The humanized antibody contains CD19 VH and CD19 VL which are selected from one of groups 1) to 8). The CD19-targeting chimeric antigen receptor contains a CD19-targeting extracellular antigen recognition domain, a hinge region, a transmembrane region, and an intracellular domain, wherein the CD19-targeting extracellular antigen recognition domain contains CD19 VH and CD19 VL which are selected from one of groups 1) to 8).

The invention discloses an antibody or an antigen binding fragment specifically binding to trop2. The antibody or the antigen binding fragment comprises heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, and light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, the amino acid sequence of the HCDR1 is as shown in SEQ ID NO.1, the amino acid sequence of the HCDR2 is as shown in SEQ ID NO.2, the amino acid sequence of the HCDR3 is as shown in SEQ ID NO.3, the amino acid sequence of the LCDR1 is as shown in SEQ ID NO.4, the amino acid sequence of the LCDR2 is as shown in SEQ ID NO.5, and the amino acid sequence of the LCDR3 is as shown in SEQ ID NO.6. The expression condition of trop2 in human breast cancer and pancreatic cancer cell membrane tissue samples can be detected through an immunohistochemical method, and the adjoint diagnostic kit for the humanized trop2 antibody coupling medicine has the advantages of assisting in precise medication and avoiding invalid treatment.

The present application provides humanized antibodies and antigen binding fragments thereof that bind to human poliovirus (PVR). The antibodies are useful in the treatment of tumors or cancers. The present application also provides a method of treating a cancer in an individual afflicted with a cancer comprising administering to the individual a therapeutically effective amount of chimeric antigen receptor (CAR) NK or T cells.

Provided are an anti-BCMA antibody, an antigen-binding fragment thereof, and a medical use thereof. Further provided are a chimeric antibody and a humanized antibody containing a CDR region of the anti-BCMA antibody, a pharmaceutical composition containing the anti-BCMA antibody or the antigen-binding fragment thereof, and the use of same as an anti-cancer drug and for treating autoimmune diseases. Particularly, provided are a humanized anti-BCMA antibody, and the use of same in the preparation of a drug for treating BCMA-mediated diseases or conditions and the use of same in disease detection and diagnosis.

Disclosed are an antibody capable of binding to thymic stromal lymphopoietin and the use thereof. Disclosed are an anti-TSLP antibody, comprising a murine antibody, chimeric antibody and humanized antibody of the light chain and heavy chain variable regions of the anti-TSLP antibody and antigen-binding fragments thereof, or a pharmaceutically acceptable salt or solvent compound thereof, and the use thereof as a drug for treating asthma, especially the use thereof in the preparation of a drug for treating TSLP-positive diseases or conditions.

Humanized antibody molecules that specifically bind to CD138 are disclosed. The humanized antibody molecules can be used to treat, prevent, and / or diagnose disorders, such as multiple myeloma.

The application discloses humanized anti-CD24 antibodies and application thereof, relates to the technical field of biological medicine, and specifically provides humanized antibodies capable of specifically recognizing CD24 and application thereof. FR regions and constant regions of a mouse-derived anti-CD24 monoclonal antibody are replaced by human-derived FR regions and constant regions, and CDR of the variable region of the mouse-derived anti-CD24 monoclonal antibody is retained, so that a series of anti-CD24 humanized monoclonal antibodies are obtained. The humanized antibodies obtained by the application have an affinity to CD24 antigens which is basically equivalent to that of a human-mouse chimeric anti-CD24 monoclonal antibody WT, and exhibit strong anti-tumor capacity in vivo.

The present invention relates to: humanized antibodies capable of specifically binding to TransMembrane 4 Superfamily Member 4 (TM4SF4) with high affinity and showing low immunogenicity in humans; and a composition for preventing and treating cancer or assisting in immune anticancer therapy, the composition comprising the humanized antibodies.

The invention provides a humanized TfR1 targeting antibody and an application of the humanized TfR1 targeting antibody. In particular, the invention provides a novel anti-TfR1 humanized antibody. The antibody disclosed by the invention can be combined with a TfR1 antigen with high specificity, and has relatively high affinity and biological activity, relatively good endocytosis activity, low immunogenicity and a stable structure. The humanized antibody provided by the invention can be used for preparing medicines for preventing or treating TfR1 related diseases.

Provided is the use of a GPRC5D single-domain antibody and a humanized antibody thereof in the construction of a CAR-T cell. The present invention specifically relates to a single-domain antibody targeting GPRC5D and a humanized antibody thereof, and tandem configurations of the antibodies. Further provided are a chimeric antigen receptor (CAR) molecule constructed by using the antibodies, a CAR-T cell and the use thereof, providing a new therapeutic option for patients with GPRC5D-positive multiple myeloma.

The invention provides an application of a GPRC5D humanized antibody and a concatemer in construction of a CAR-T cell, particularly relates to a GPRC5D-targeted single-domain antibody and the humanized antibody thereof, and a serial configuration of the antibody, and also provides a chimeric antigen receptor (CAR) molecule constructed by using the antibody, the CAR-T cell and application thereof. Under a standardized condition, the tandem configuration shows remarkably improved tumor cell killing compared with a corresponding monomer configuration so as to realize a high CAR-T maximum effect, and a new treatment choice is provided for GPRC5D positive multiple myeloma patients.

Antibodies that specifically bind to epidermal growth factor receptor variant III (EGFRvIII) and / or gene-amplified EGFR (e.g., humanized monoclonal antibodies and antigen-binding fragments), as well as conjugates and chimeric antigen receptors (CARs) containing such antibodies, are disclosed herein. Nucleic acid molecules encoding the antibodies, conjugates, or CARs disclosed herein, and host cells expressing the nucleic acid molecules are also provided. Methods for treating or detecting tumors, such as tumors expressing EGFRvIII and / or gene-amplified EGFR, using the disclosed compositions are further disclosed.

The application relates to the field of biomedical technology, in particular to a monoclonal antibody specifically combined with EsxA and a therapeutic reagent; the monoclonal antibody comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises three complementarity determining regions VLCDR1, VLCDR2 and VLCDR3, the heavy chain variable region comprises three complementarity determining regions VHCDR1, VHCDR2 and VHCDR3, the light chain variable region is an amino acid sequence identical to SEQ.ID.NO.1 at least 90%, 95%, 96%, 97%, 98%, 99% or 100%, and the heavy chain variable region is an amino acid sequence identical to SEQ.ID.NO.2 at least 90%, 95%, 96%, 97%, 98%, 99% or 100%; the therapeutic reagent comprises the monoclonal antibody, a single-chain antibody, a human-mouse chimeric antibody or a humanized antibody; the monoclonal antibody provided by the application is high in specificity, neutralization activity and protective power and is directed to EsxA, has the characteristics of mediating complement-dependent cytotoxicity, is excellent in in-vivo antibacterial activity and can support the construction of an anti-EsxA chimeric or humanized genetically engineered antibody with neutralization activity.

The present application belongs to the technical field of cellular immunization engineering, and particularly relates to a polypeptide specifically recognizing PSCA and application thereof. The polypeptide provided by the present application specifically recognizes PSCA and has good affinity performance. The polypeptide specifically targeting PSCA provided by the present application can mark PSCA positive cells, combine with PSCA antigen and PSCA positive cells, and can be used as a detection reagent for PSCA molecules and an in-vivo tracing labeling reagent. The polypeptide specifically targeting PSCA provided by the present application can also be used in an extracellular antigen recognition region of a chimeric antigen receptor, and can be used in an immune cell treatment drug targeting PSCA to kill malignant tumors expressing PSCA. The polypeptide specifically recognizing PSCA of the present application is derived from a natural full human antibody, and compared with a mouse-derived antibody, a chimeric antibody and a humanized antibody, the immunogenicity is greatly reduced, and the safety can be maximally ensured in clinical application.

The present invention relates to humanized anti-Lewis Y antibodies that specifically bind Lewis Y and do not show any cross-reactivity. In particular, the humanized anti-Lewis Y antibodies do not bind to Lewis b or any other blood group carbohydrate antigen. In particular, the present invention relates to humanized anti-Lewis Y antibodies for use in the treatment of cancer.

The invention provides an anti-Claudin18.2 humanized single-domain antibody and a preparation method of the anti-Claudin18.2 humanized single-domain antibody. Specifically, the invention provides a Claudin18.2-targeted single-domain antibody, a humanized antibody thereof, a derivative protein, a gene sequence for encoding the Claudin18.2-targeted single-domain antibody, and an expression vector and an expression system for producing the Claudin18.2-targeted single-domain antibody. The single-domain antibody has high specificity, is combined with Claudin18.2 with high affinity and is basically not combined with Claudin18.1, and the single-domain antibody provides a research and development basis for development of antibody drugs, antibody coupling drugs and multi-specific antibody drugs.

The present invention relates to the use of an antibody or an immunologically active fragment thereof, which specifically binds to integrin β2, as an immuno-oncology agent. The chimeric and humanized antibodies of the present invention specifically bind to integrin β2, which is a tumor-specific antigen and is expressed on the cell membrane of M2 tumor-associated macrophages, and thus can be used as an antibody therapeutic agent for cancer treatment using a cancer cell death mechanism by immune cell activation, an antibody therapeutic agent for cancer treatment, or a cell therapeutic agent for cancer treatment, and can also be used for cancer diagnosis.